Core Viewpoint - Zai Ding Pharmaceutical (ZLAB.US) shares rose over 7% to $18.84, following the approval of a new drug for schizophrenia treatment by the National Medical Products Administration of China, marking a significant breakthrough in the field [1] Company Summary - Zai Ding Pharmaceutical announced the approval of its new drug, Nemonapride Chloride Capsules (Kai Jie Le), for the treatment of adult schizophrenia [1] - This drug represents the first new treatment mechanism for schizophrenia approved in over 70 years, indicating a fundamental advancement in schizophrenia therapy [1] Market Reaction - Following the announcement, Zai Ding Pharmaceutical's stock price increased by 7% in the U.S. market and 6.24% in the Hong Kong market [1]
新药凯捷乐在中国获批上市 再鼎医药(ZLAB.US)涨超7%